Company intelligence / Profile preview

Oxford BioMedica

Oxford, Oxfordshire, United Kingdomoxb.com ↗

Ownership: Public · OXB
Employees: ~500
Development stage: Commercial

Overview

Leading global CDMO/platform provider enabling cell/gene therapies via advanced viral vectors used worldwide—including several marketed products—with deep expertise spanning R&D through commercial supply.

Therapeutic areas: OphthalmologyOncologyNeurology
Modalities: Gene therapyCell therapyViral vector
Industry: Contract Manufacturing Organization

Partnerships

Novartis CAR-T collaborationother major pharma partnerships

Financials

Market cap: $26.5B
Total revenue: $2.3B

Beyond the preview

Go deeper on Oxford BioMedica.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Oxford BioMedica.

Explore the full profile